- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00371761
PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)
March 8, 2017 updated by: Merck Sharp & Dohme LLC
An Open-Label, Randomized, Comparative Study With PegIntron vs. Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan
This is an open label, randomized, comparative, multi-center study.
Subjects will be screened within 2 weeks prior to study entry to establish eligibility.
Subjects who meet all the selection criteria will be randomly assigned 1:1 to (1) once-a-week, subcutaneous Pegylated interferon alfa-2b (PegIntron) (1.5 mcg/kg body weight) or (2) oral adefovir 10 mg daily.
The treatment phase will be 24 weeks for PegIntron and 48 weeks for adefovir.
All subjects completing the assigned treatment phase will be followed up for an additional 48 weeks for PegIntron and 24 weeks for adefovir as observation phase.
The primary objective is to establish the efficacy profile of PegIntron.
Secondary objectives are to compare the efficacy profile of PegIntron with that of adefovir, compare efficacy of PegIntron in lamivudine-naïve and lamivudine-experienced subjects, and to establish the safety profile of PegIntron in treating patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult male or female, 18 to 70 years of age.
- Documented positive serum hepatitis B surface antigen (HBsAg) for a minimum of 6 months prior to randomization.
Hepatitis B virus (HBV) replication and hepatitis documented by:
- Serum HBV DNA (Hepatitis B Virus Deoxyribonucleic acid) >= 10^5 copies/mL within 3 months prior to entry
- Positive serum hepatitis B e antigen (HBeAg) within 3 months prior to entry
- Documented presence of ALT (Alanine Aminotransferase) twice (1 month apart) within 3 months prior to entry (2 to 10 folds above the upper normal level)
- Liver biopsy finding shows evidence of chronic hepatitis without liver cirrhosis, document acceptable if no anti-HBV treatment within 1 year prior to randomization
- Naïve or exposed to lamivudine (3 months treatment-free interval prior to randomization)
- Adequate renal function (creatinine within normal upper limit).
- Compensated liver disease with certain minimum hematological and serum biochemical criteria.
- Thyroid stimulating hormone (TSH) and free T4 within normal ranges.
- Negative antibody to hepatitis C and hepatitis D.
- Negative antibody to human immunodeficiency virus.
- Negative evidence for hepatocellular carcinoma by alfa-fetoprotein and ultrasound within 1 month prior to randomization.
Exclusion Criteria:
- Women who are pregnant or nursing.
- Prior treatment for hepatitis with any interferon or adefovir, or other investigational anti-virus agents.
- Prior treatment for hepatitis with immunomodulatory drug within 2 years prior to randomization.
- Suspected hypersensitivity to interferon or adefovir.
- Liver cirrhosis.
- History of severe psychiatric disease, especially depression.
- Concurrent malignancies (including hepatocellular carcinoma).
- Unstable or significant cardiovascular diseases.
- Prolonged exposure to known hepatotoxins.
- History of thyroid disease poorly controlled on prescribed medication.
- Poorly controlled diabetes mellitus.
- Have suspected or confirmed significant hepatic disease from an etiology other than HBV.
- Severe renal disease or myeloid dysfunction.
- History of organ transplantation other than cornea and hair transplant.
- Any medical condition requiring chronic systemic administration of steroids.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PegIntron
PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
|
Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Other Names:
|
ACTIVE_COMPARATOR: Adefovir
Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
|
10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response
Time Frame: At Week 72 [for Pegylated interferon alfa-2b (PegIntron), at 48 weeks post PegIntron treatment for up to 24 weeks; for Adefovir, at 24 weeks post adefovir treatment for up to 48 weeks]
|
|
At Week 72 [for Pegylated interferon alfa-2b (PegIntron), at 48 weeks post PegIntron treatment for up to 24 weeks; for Adefovir, at 24 weeks post adefovir treatment for up to 48 weeks]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (ACTUAL)
February 1, 2009
Study Completion (ACTUAL)
February 1, 2009
Study Registration Dates
First Submitted
August 31, 2006
First Submitted That Met QC Criteria
August 31, 2006
First Posted (ESTIMATE)
September 4, 2006
Study Record Updates
Last Update Posted (ACTUAL)
April 6, 2017
Last Update Submitted That Met QC Criteria
March 8, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
- Peginterferon alfa-2b
- Adefovir
- Adefovir dipivoxil
Other Study ID Numbers
- P04498
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic (CHB)
-
Qin NingRecruitingthe Effect of NAFLD on CHBChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Hannover Medical SchoolGerman Center for Infection ResearchRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruiting
Clinical Trials on Pegylated interferon alfa-2b (PegIntron)
-
Amsterdam UMC, location VUmcMerck Sharp & Dohme LLC; Novartis; Uppsala University HospitalTerminatedChronic Myeloid LeukemiaNetherlands, Denmark, Sweden, Finland, Norway
-
National Cancer Institute (NCI)National Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV InfectionUnited States
-
The Wistar InstituteUniversity of Pennsylvania; Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
HepNet Study House, German LiverfoundationHannover Medical SchoolTerminatedHepatitis C, ChronicGermany
-
Merck Sharp & Dohme LLCCompletedHepatitis C | Hepatitis C, Chronic
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHepatitis D, Chronic | Hepatitis B, Chronic
-
Merck Sharp & Dohme LLCBioikos Ambiente SrlCompleted
-
Merck Sharp & Dohme LLCCompleted